SONATA launches doctor-led preventive healthcare membership
SONATA has launched a doctor-led preventive healthcare membership in New York, San Francisco, and Los Angeles, priced at $2,500 annually. The service features deep clinical testing, including whole-genome sequencing and biomarker analysis, integrated with clinical AI and care from board-certified physicians. The company is backed by investors including Lux Capital and Box Group.

*this image is generated using AI for illustrative purposes only.
SONATA has launched a doctor-led preventive healthcare membership in New York, San Francisco, and Los Angeles. The service integrates deep biological testing, board-certified physicians, and clinical AI to create personalized care plans aimed at identifying health risks before disease onset. The founding membership is priced at $2,500 annually.
The membership model addresses the gap between abundant health data and the lack of clinical guidance to interpret it. SONATA performs deep clinical testing not typically included in routine primary care, such as whole-genome sequencing and DNA methylation analysis, and combines these results with a member's medical history and wearable data.
Membership Features
SONATA's offering includes a range of diagnostic and monitoring services designed to provide a comprehensive view of a member's health. The care model is continuous rather than a one-time test, with plans that evolve as a member's biology and goals change.
| Feature | Description |
|---|---|
| Physician Access | Unlimited visits with a physician-led care team |
| Testing | In-home blood testing and more than 140 blood biomarkers |
| Genomics | Whole-genome sequencing and polygenic risk analysis |
| Epigenetics | DNA methylation analysis and biological age measurement |
| Integration | Wearable and health-record data integration |
Technology and Care Model
SONATA utilizes clinical AI developed in-house to synthesize complex information across genomics, biomarkers, medical history, and ongoing care trends. While the AI assists in data processing, all clinical decisions, including interpretation, diagnosis, and prescribing, remain physician-led.
"Modern medicine is built on population averages, but no individual is the average," said David Deng, co-founder and CTO of SONATA. "SONATA's clinical AI synthesizes each member's genomics, epigenetics, biomarkers, and health records against clinical guidelines and the latest peer-reviewed research, so physicians can focus their time on listening to patients and building truly personalized care plans."
The company was co-founded by Sagan Schultz, MD, MBA, and David Deng. Schultz is a former McKinsey healthcare consultant and the first product manager at Linear, while Deng was a first-10 engineer at Ramp and a former member of the clinical genomics team at Flatiron Health. SONATA is backed by Lux Capital, Box Group, and Sunflower Capital.
Historical Stock Returns for Sonata Software
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.24% | -6.54% | 0.0% | -6.52% | -32.72% | -1.81% |
Does SONATA plan to expand its services beyond New York, San Francisco, and Los Angeles in the near future?
How will SONATA navigate regulatory challenges regarding the use of clinical AI in diagnostics and prescribing?
What are the potential barriers to widespread adoption given the $2,500 annual price point?


































